High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.

Sims, Joshua J; Lian, Sharon; Meggersee, Rosemary L; Kasimsetty, Aradhana; Wilson, James M

Sims, Joshua J; Lian, Sharon; Meggersee, Rosemary L; Kasimsetty, Aradhana; Wilson, James M.

Affiliation

Sims JJ; Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Lian S; Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Meggersee RL; Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Kasimsetty A; Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Wilson JM; Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.

PLoS One ; 17(8): e0271359, 2022.

Article in En | MEDLINE | ID: mdl-36006993

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / Angiotensin-Converting Enzyme 2 / COVID-19 Drug Treatment Limits: Animals / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google